Latest update on ABT-199 an interview of Dr John Seymour Australian lead investigator by Patient Power

"Dr. John Seymour, a CLL researcher, shares an update about an ongoing trial using the Bcl-2 inhibitor ABT-199, which received a dose modification following safety concerns. Dr. Seymour explains Phase I trial data that demonstrates the therapy's balance of safety and efficacy as well its promising potential for combination with other agents.

Last edited by

2 Replies


You may also like...